Vieira Roberto Wandenkolk sold $6.5M of CORT

Vieira Roberto Wandenkolk (President, Oncology) sold 58,333 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $110.76 ($109.35–$115.44, $6.46M total) across 7 trades on 2026-09-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Vieira Roberto Wandenkolk
Published Sep 4, 2026, 1:02 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 1:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CORT
Neutral
medium confidence
Mentioned
$CORT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTNeutralLow
01

Why it matters

The disclosed sale is a routine 10b5‑1 transaction, offering limited new information for traders.

02

Market read

Routine insider sale with modest size; minimal impact on broader market.

03

What to watch

Potential upcoming clinical data releases could offset any negative sentiment from the insider sale.

Relevance 5/10Novelty 4/10Timing: filing reported Sep 3, 2026 (after‑market)

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$CORTNeutralMedium confidence
Context

President of Oncology sold 58,333 shares for $6.46M via a 10b5‑1 plan on Sep 2, 2026.

Expected impact

minor downward pressure, limited to short‑term volatility

Evidence & confidence

Sale size is modest relative to market cap and follows a 10b5‑1 plan, suggesting no urgent information asymmetry.

Market effects

Limited; reflects routine insider activity in biotech sector.

None

None

Counterpoint

Despite the sale, the company's pipeline may still drive upside.

Key entities

  • Corcept Therapeutics Inc.

    Biopharma focused on cortisol‑related therapies.

  • Vieira Roberto Wandenkolk

    President, Oncology at Corcept Therapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CORTMedAI 8/10

Corcept reports 8-year response in vulvar cancer case study

Corcept Therapeutics (CORT) reported a case study in ESMO Rare Cancers showing an 8-year response to relacorilant plus nab-paclitaxel in a metastatic vulvar cancer patient. The company noted this is a single case and not representative of the broader population. Relacorilant is FDA-approved for platinum-resistant ovarian cancer but not vulvar cancer. Corcept is developing the drug for other cancer types.

$CORTMed

Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64%

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $91M, up 64% YoY, driven by Lifyorli's growth. Management expects Lifyorli to move earlier in treatment sequences and sees potential for $1B in revenue. The company reiterated its 2026 guidance of $1.1B-$1.2B, citing strong performance in endocrinology and oncology. CEO Belanoff discussed upcoming clinical trials and potential combinations for Lifyorli.

$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.